# Clinical and Microbiological Efficacy of CSE-1034 in Treatment of Acute Bacterial Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

## Authors

- Shao-Huan Lan ([ORCID](https://orcid.org/0000-0002-8663-3161)) — School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian, China
- Chien-Ming Chao ([ORCID](https://orcid.org/0000-0003-0235-9060)) — Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan
- Shen-Peng Chang ([ORCID](https://orcid.org/0000-0002-9361-4348)) — Department of Pharmaceutical Sciences, Yijia Pharmacy, Tainan, Taiwan
- Li-Chin Lu ([ORCID](https://orcid.org/0000-0002-4289-0780)) — School of Management, Putian University, Putian, China
- Tzu-Liang Hsu ([ORCID](https://orcid.org/0000-0003-4235-3923)) — Department of Orthopedic Surgery, Tung’s Taichung MetroHarbor Hospital, Wuqi District, Taichung City, Taiwan

## Article information

- **Journal:** The Ulutas Medical Journal (Ulutas Med J), ISSN 2149-388X
- **Issue:** Volume 8, Issue 4 (2022), pages 118–126
- **Article type:** Meta-Analysis
- **Published online:** 2022-12-05
- **DOI:** [10.5455/umj.20220622065911](https://doi.org/10.5455/umj.20220622065911)
- **Licence:** [CC BY-NC 4.0](https://creativecommons.org/licenses/by-nc/4.0/)
- **Article page:** https://www.ulutasmedicaljournal.com/?mno=65602
- **PDF:** https://www.ulutasmedicaljournal.com/pdf/65602.pdf

## Abstract

This study aimed to conduct a meta-analysis to assess the clinical and microbiological efficacy of CSE-1034 for treating acute bacterial infections in adult patients. PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched from their inception until April 2022 for relevant randomized controlled trials (RCTs). Only RCTs evaluating CSE-1034 and comparators for treating acute bacterial infections in adult patients were included. The primary outcome was the clinical response rate at the end of treatment (EOT) evaluation. Five RCTs were included. A total of 950 patients (n:638 in the UTI group, n:186 in the lower respiratory tract infection group, n:70 in the bone and joint infection group, and n:56 in SSSI) were included in this meta-analysis; 478 and 472 patients received CSE-1034 and comparators, respectively. Overall, CSE-1034 had a higher clinical cure rate at EOT than did the comparators (95.3% [384/403] vs. 81% [319/394], RR, 1.2; 95%CI, 1.04-1.39; I2=92%). Moreover, the clinical failure rate of CSE-1034 was lower than that of the comparators (RR, 0.04; 95%CI, 0.01-0.13; I2=0%). CSE-1034 also had a higher microbiological eradication rate than the comparators (92.9% [315/339] vs. 71.1% [216/304], RR, 1.53; 95%CI, 1.06-2.21; I2=97%). The clinical and microbiological efficacy of CSE-1034 is comparable or even superior in treating acute bacterial infections.

## Keywords

CSE-1034; acute bacterial infection; urinary tract infection; lower respiratory tract infection; community-acquired bacterial pneumonia

## How to cite

Lan SH, Chao CM, Chang SP, Lu LC, Hsu TL. Clinical and Microbiological Efficacy of CSE-1034 in Treatment of Acute Bacterial Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ulutas Med J. 2022;8(4):118-126. doi:10.5455/umj.20220622065911

## References

1. JL, Sahu M, Sanjith S, Bhalekar P, Keny D. Waging war against extended spectrum Beta lactamase and metallobetalactamase producing pathogens- novel adjuvant antimicrobial agent cse1034- an extended hope. J Clin Diagn Res. 2014;8(6):20-3 https://doi.org/10.7860/jcdr/2014/8802.4504
2. Gupta R. Antibiotic adjuvant therapy for multi-drug resistant carbapenemases producing Klebsiella pneumoniae associated sepsis: A case study. J Clin Diagn Res. 2016;10(4):08-9 https://doi.org/10.7860/jcdr/2016/17544.7697
3. Chakravorty S, Arun P. Antibiotic/adjuvant combinations (ceftriaxone + sulbactam + adjuvant disodium edetate) as an alternative empiric therapy for the treatment of nosocomial infections: Results of a retrospective study. Indian J Cancer. 2017;54(4):685-90 https://doi.org/10.4103/ijc.ijc_364_17
4. Chaudhary M, Mir MA, Ayub SG. Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study. Braz J Infect Dis. 2017;21(4):408-17 https://doi.org/10.1016/j.bjid.2017.02.007
5. Mir MDA, Chaudhary S, Payasi A, Sood R, Mavuduru RS, Shameem M. CSE (Ceftriaxone+ sulbactam+ disodium EDTA) versus meropenem for the treatment of complicated urinary tract Infections, including acute pyelonephritis: PLEA, a double-blind, randomized noninferiority trial. Open Forum Infect Dis. 2019;6(10):373 https://doi.org/10.1093/ofid/ofz373
6. Chaudhary M, Ayub SG, Mir MA. CSE -1034 versus ceftriaxone: Efficacy and safety analysis from a randomized, open-labeled phase III study in complicated urinary tract infections. J Glob Infect Dis. 2018;10(4):188-95 https://doi.org/10.4103/jgid.jgid_98_17
7. Chaudhary M, Ayub SG, Mir MA. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia. J Infect Public Health. 2018;11(5):691-7 https://doi.org/10.1016/j.jiph.2018.04.006
8. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:5928 https://doi.org/10.1136/bmj.d5928
9. Chaudhary M PA. A randomized, open-label, prospective, multicenter phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections.J Pharm Res. 2013;6(4):40-414 https://doi.org/10.1016/j.jopr.2013.04.011
10. Chaudhary M, Payasi A. Clinical, microbial efficacy and tolerability of Elores, a novel antibiotic adjuvant entity in ESBL producing pathogens: Prospective randomized controlled clinical trial. J Pharm Res 2013;7(4):275-280 https://doi.org/10.1016/j.jopr.2013.04.017
11. Patil UN, Jambulingappa KL. A combination strategy of ceftriaxone, sulbactam and disodium edetate for the teatment of multi-drug resistant (MDR) septicaemia: A retrospective, observational study in Indian tertiary care hospital. J Clin Diagn Res. 2015;9(11):29-32 https://doi.org/10.7860/jcdr/2015/14129.6840
12. Lai CC, Chen CC, Lu YC, Chuang YC, Tang HJ. In vitro activity of cefoperazone and cefoperazone -sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Infect Drug Resist. 2019;12:25-9 https://doi.org/10.2147/idr.s181201
13. Lai CC, Chen CC, Lu YC, Lin TP, Chuang YC, Tang HJ. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organism. Infect Drug Resist. 2018;11: 1441-5 https://doi.org/10.2147/idr.s175257
14. Lan SH, Chang SP, Lai CC, Lu LC, Tang HJ. Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis. Medicine (Baltimore). 2020;99(8):19321 https://doi.org/10.1097/md.0000000000019321
15. Cheng IL, Chen YH, Lai CC, Tang HJ. The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-A meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2020;55(2):105858 https://doi.org/10.1016/j.ijantimicag.2019.11.015
16. Lin WT, Lai CC, Cheong CU. Novel beta-Lactam/beta-Lactamase combination versus meropenem for treating nosocomial pneumonia. Antibiotics (Basel). 2019;8(4):219 https://doi.org/10.3390/antibiotics8040219
17. Lu LC, Lai CC, Chang SP, Lan SH, Hung SH, Lin WT. Novel beta-Lactam/beta-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2020;99(19):19960 https://doi.org/10.1097/md.0000000000019960
18. Tan CK, Lai CC, Chao CM. Ceftazidime-avibactam versus meropenem for the treatment of complicated intra-abdominal infections. Antibiotics (Basel). 2019;8(4):255 CSE-1034 in Treatment of Acute Bacterial Infections Shao-Huan Lan et al. https://doi.org/10.3390/antibiotics8040255